Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors

被引：0
|
作者：
Nakahara, Y. [1 ]
Himuro, H. [2 ]
Igarashi, Y. [2 ]
Kouro, T. [2 ]
Higashijima, N. [2 ]
Matsuo, N. [3 ]
Murakami, S.
Wei, F. [2 ]
Horaguchi, S. [2 ]
Tsuji, K. [2 ]
Mano, Y. [2 ]
Saito, H. [4 ]
Azuma, K. [3 ]
Naoki, K.
Sasada, T. [2 ]
机构：
[1] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan
[2] Kanagawa Canc Ctr Res Inst, Yokohama, Kanagawa, Japan
[3] Kurume Univ, Sch Med, Kurume, Fukuoka, Japan
[4] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Immune checkpoint inhibitors; Soluble PD-1; Soluble PD-L1;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP11.01-11
引用
收藏
页码：S614 / S614
页数：1
相关论文
共 50 条
  • [1] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Higashijima, Naoko
    Matsuo, Norikazu
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (08) : 2829 - 2840
  • [2] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Hidetomo Himuro
    Yoshiro Nakahara
    Yuka Igarashi
    Taku Kouro
    Naoko Higashijima
    Norikazu Matsuo
    Shuji Murakami
    Feifei Wei
    Shun Horaguchi
    Kayoko Tsuji
    Yasunobu Mano
    Haruhiro Saito
    Koichi Azuma
    Tetsuro Sasada
    Cancer Immunology, Immunotherapy, 2023, 72 : 2829 - 2840
  • [3] Plasma soluble PD-1/PD-L1 for prediction of prognosis in NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    CANCER SCIENCE, 2024, 115 : 1381 - 1381
  • [4] Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors
    Castello, A.
    Rossi, S.
    Toschi, L.
    Lopci, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S66 - S67
  • [5] Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients
    He, Jiabei
    Pan, Yuanqing
    Guo, Yang
    Li, Baolan
    Tang, Yu
    JOURNAL OF IMMUNOTHERAPY, 2020, 43 (05) : 156 - 164
  • [6] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Skalniak, Lukasz
    Zak, Krzysztof M.
    Musielak, Bogdan
    Rudzinska-Szostak, Ewa
    Berlicki, Lukasz
    Kocik, Justyna
    Grudnik, Przemyslaw
    Sala, Dominik
    Zarganes-Tzitzikas, Tryfon
    Shaabani, Shabnam
    Doemling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735
  • [7] Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
    Jorgensen, Jan Trost
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (02) : 131 - 133
  • [8] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
    Ma, K.
    Guo, Y.
    Wang, Y.
    Wang, X.
    Xu, Y.
    Sun, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
  • [9] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [10] PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
    Yang, Tianrui
    Kong, Ziren
    Ma, Wenbin
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (02) : 546 - 553
12345